“…Some studies show that the IRE1‐XBP1 pathway is not activated in oligodendrocytes under normal or disease conditions (Hussien et al, ; Stone & Lin, ); however, other studies show opposite results (Mháille et al, ; Ní Fhlathartaigh et al, ; Naughton, McMahon, & FitzGerald, ). A number of studies demonstrate that the PERK branch can positively or negatively influence oligodendrocyte viability in myelin disorders (Southwood, Garbern, Jiang, & Gow, ; Lin, Harding, Ron, & Popko, ; Lin et al, , , ; Hussien, Cavener, & Popko, ). Nevertheless, despite observation of activation of the ATF6α branch in oligodendrocytes under normal and disease conditions (Mháille et al, ; Naughton et al, ; Stone & Lin, ), the effects of ATF6α activation on these cells remains unknown.…”